Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
NeoStrata Company, Inc. |
---|---|
Information provided by: | NeoStrata Company, Inc. |
ClinicalTrials.gov Identifier: | NCT00769184 |
This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of follow-up. The purpose of the study is to compare the safety and effectiveness of combining and then following a high potency topical corticosteroid treatment with LCD treatment for moderate-to-severe localized plaque psoriasis.
Condition | Intervention |
---|---|
Psoriasis |
Drug: clobetasol + LCD Drug: Clobetasol + Placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Steroid-Sparing Effect of Supplemental LCD Treatment in Patients With Moderate-to-Severe Localized Psoriasis Lesions: a Pilot Study. |
Estimated Enrollment: | 15 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
|
Drug: clobetasol + LCD
clobetasol: 2 applications / day LCD Solution: 2 applications / day
|
2: Placebo Comparator
steroid + placebo treatment (2 weeks), placebo alone treatment (4 weeks)
|
Drug: Clobetasol + Placebo
Clobetasol: 2 applications / day Placebo Solution: 2 applications / day
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jerry Bagel, MD | (609) 443-4500 | njpsoriasis@aol.com |
United States, New Jersey | |
Windsor Dermatology | Recruiting |
East Windsor, New Jersey, United States, 08520 | |
Contact: Jerry Bagel, MD 609-443-4500 njpsoriasis@aol.com | |
Principal Investigator: Jerry Bagel, MD |
Responsible Party: | NeoStrata Company, Inc. ( Barbara Green ) |
Study ID Numbers: | 08-LCDSTRD |
Study First Received: | October 7, 2008 |
Last Updated: | October 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00769184 |
Health Authority: | United States: Institutional Review Board |
chronic plaque psoriasis |
Clobetasol Skin Diseases Psoriasis Skin Diseases, Papulosquamous |
Anti-Inflammatory Agents Therapeutic Uses Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Hormones Glucocorticoids Pharmacologic Actions |